US3632741A - Diethylaminoethyl dextran as an adjuvant for vaccines for active immunization - Google Patents

Diethylaminoethyl dextran as an adjuvant for vaccines for active immunization Download PDF

Info

Publication number
US3632741A
US3632741A US35917A US3632741DA US3632741A US 3632741 A US3632741 A US 3632741A US 35917 A US35917 A US 35917A US 3632741D A US3632741D A US 3632741DA US 3632741 A US3632741 A US 3632741A
Authority
US
United States
Prior art keywords
adjuvant
vaccines
vaccine
dextran
diethylaminoethyl dextran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US35917A
Other languages
English (en)
Inventor
Gunther Wittmann
Kurt Bauer
Manfred Mussgay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of US3632741A publication Critical patent/US3632741A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/815—Viral vaccine for porcine species, e.g. swine

Definitions

  • This invention relates to new vaccines containing adjuvants and more particularly to vaccines containing adjuvants comprising diethylaminoethyl dextran,
  • adjuvants depending on the antigen which is used with them or depending on the type of animal in which the vaccine is used, give variably favorable or less favorable results. All that the above-mentioned adjuvants have in common is that they constitute a large portion of the vaccine, namely 2550%. In addition and especially in the case of mineral oil-containing adjuvants, strong acid reactions may occur at the place of vaccination.
  • (b) is relatively slightly toxic, so that only slight reactions to vaccination occur, which lead to no permanent changes at the places of vaccination, which is particularly of importance in the case of slaughter animals;
  • the adjuvant and resulting new vaccine of the present invention satisfy these requirements.
  • a further object of the present invention is to provide diethylaminoethyl dextran as an adjuvant to antigen solutions in vaccines.
  • the present invention provides a new vaccine in which diethylaminoethyl dextran (DEA-ED) is added directly as an adjuvant to the antigen solution.
  • DEA-ED diethylaminoethyl dextran
  • the present invention relates to a new vaccine in which diethylaminoethyl dextran (DEA'E-D) is added directly as an adjuvant to the antigen solution. Besides a considerable increase in the antibody formation and prolonged persistence of the antibody titers, this new vaccine also causes a considerable raising of the immunity in the case of the subjects vaccinated, as compared with application of the antigen alone.
  • DEA'E-D diethylaminoethyl dextran
  • the proportion of the diethylaminoethyl dextran adjuvant to be employed according to the present invention is about 5 to 250 mg. of DEAEDextran per ml. of innoculation serum and more preferably about 50 mg. of DEAE-Dextran per ml. of serum,
  • tribufier is to be added.
  • the mixture of DEAE-Dextran and the added bufiFer substance is heated in an autoclave for 2030 minutes at C. to C. for the purpose of sterilization.
  • the antigen solution is added to the solidified DEAEDextran and the mixture is kept at least 48 hours with occasional shaking at a suitable temperature.
  • the DEAE-Dextran usually is dissolved.
  • the vaccines are shaken for 1 hour and they are then allowed to stand until their use, once more for at least 24 hours at a suitable temperature.
  • aminoethyl dextran adjuvant is present in an amount of about 5 to 250 mg. per ml. of innoculation serum.
  • Vaccines according to claim 3 wherein said antigens are sensitive to acid and the pH value of the diethylaminoethyl dextran is balanced out by the addition of a buffer substance.
  • Vaccine-s according to claim 7 wherein the bufier solution and diethylaminoethyl dextran are heated at C. to C. prior to addition to the antigen.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US35917A 1969-05-13 1970-05-08 Diethylaminoethyl dextran as an adjuvant for vaccines for active immunization Expired - Lifetime US3632741A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE1924304A DE1924304C3 (de) 1969-05-13 1969-05-13 Diäthylaminoäthyldextran (DEAE-D) als Adjuvans für Impfstoffe zur aktiven Immunisierung von Säugetieren

Publications (1)

Publication Number Publication Date
US3632741A true US3632741A (en) 1972-01-04

Family

ID=5734041

Family Applications (1)

Application Number Title Priority Date Filing Date
US35917A Expired - Lifetime US3632741A (en) 1969-05-13 1970-05-08 Diethylaminoethyl dextran as an adjuvant for vaccines for active immunization

Country Status (9)

Country Link
US (1) US3632741A (es)
JP (1) JPS4921049B1 (es)
BE (1) BE750349A (es)
CA (1) CA918071A (es)
DE (1) DE1924304C3 (es)
ES (1) ES379642A1 (es)
FR (1) FR2051519B1 (es)
GB (1) GB1256457A (es)
NL (1) NL169031B (es)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0014995A2 (en) * 1979-02-21 1980-09-03 Pharmacia Ab Immunisation agent, a method of preparing the same and use thereof for producing antisera
US4351827A (en) * 1979-07-17 1982-09-28 Gist-Brocades N.V. Novel polyvalent virus vaccine
US4358438A (en) * 1979-07-17 1982-11-09 Gist-Brocades N.V. Novel polyvalent virus vaccine against rabies and canine distemper
US5110794A (en) * 1987-01-30 1992-05-05 Abbott Laboratories Method of immunization with partially cationized substances and said partially cationized substances
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
EP1784210A2 (en) * 2004-08-04 2007-05-16 Cytos Biotechnology AG Carrier conjugates of gnrh-peptides
US9149520B2 (en) 1999-01-08 2015-10-06 Zoetis Services Llc Saponin adjuvant compositions and methods relating thereto
CN109663126A (zh) * 2019-03-01 2019-04-23 龙阔（苏州）生物工程有限公司 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10141748A1 (de) * 2001-08-29 2003-06-26 Janastyle Gmbh Schutzvorrichtung
CN112516325B (zh) * 2019-09-18 2023-12-08 洛阳赛威生物科技有限公司 一种稳定的口蹄疫疫苗组合物及其应用

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0014995A2 (en) * 1979-02-21 1980-09-03 Pharmacia Ab Immunisation agent, a method of preparing the same and use thereof for producing antisera
EP0014995A3 (en) * 1979-02-21 1981-08-05 Pharmacia Ab Immunisation agent, a method of preparing the same and use thereof for producing antisera
US4351827A (en) * 1979-07-17 1982-09-28 Gist-Brocades N.V. Novel polyvalent virus vaccine
US4358438A (en) * 1979-07-17 1982-11-09 Gist-Brocades N.V. Novel polyvalent virus vaccine against rabies and canine distemper
US5110794A (en) * 1987-01-30 1992-05-05 Abbott Laboratories Method of immunization with partially cationized substances and said partially cationized substances
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US9149520B2 (en) 1999-01-08 2015-10-06 Zoetis Services Llc Saponin adjuvant compositions and methods relating thereto
US9579379B1 (en) * 1999-01-08 2017-02-28 Zoetis Services Llc Saponin adjuvant compositions and methods relating thereto
EP1784210A2 (en) * 2004-08-04 2007-05-16 Cytos Biotechnology AG Carrier conjugates of gnrh-peptides
CN109663126A (zh) * 2019-03-01 2019-04-23 龙阔（苏州）生物工程有限公司 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗

Also Published As

Publication number Publication date
FR2051519B1 (es) 1974-04-12
DE1924304B2 (de) 1979-10-25
JPS4921049B1 (es) 1974-05-29
DE1924304A1 (de) 1970-12-17
DE1924304C3 (de) 1980-07-17
BE750349A (fr) 1970-11-13
NL7006934A (es) 1970-11-17
CA918071A (en) 1973-01-02
ES379642A1 (es) 1973-01-16
GB1256457A (en) 1971-12-08
FR2051519A1 (es) 1971-04-09
NL169031B (nl) 1982-01-04

Similar Documents

Publication Publication Date Title
JP3814290B2 (ja) 抗原用のアジュバントおよびその製法ならびに用途
EP0129923B1 (en) Method of preparing adjuvanted live vaccines and adjuvanted live vaccines thus obtained
US3632741A (en) Diethylaminoethyl dextran as an adjuvant for vaccines for active immunization
US2110208A (en) Antigen preparations
JP2756321B2 (ja) 水酸化亜鉛または水酸化鉄をアジュバントとして含有する抗原溶液
Clark et al. Studies into immunisation of cattle against interdigital necrobacillosis
US3354038A (en) Serial passaging tissue cultured canine distemper virus to form attenuated vaccine short of virus-antigenicity decreasing passages
Morgan Some Manifestations of Animal Diseases Transmissible to Man: Brucellosis in Animals: Diagnosis and Control
Foggie Preparation of vaccines against enzootic abortion of ewes. A review of the research work at the Moredun Institute.
US3492400A (en) Oral immunization of salmonids against furunculosis,and alum-precipitated aeromonas salmonicida antigenic fraction therefor
US3435112A (en) Repository vaccine and method of preparing the same
US3048524A (en) Process of producing infectious bovine rhinotracheitis vaccine and product thereof
US3000788A (en) Propagation of modified infectious canine hepatitis virus in tissue cultures of pig kidney and the preparation of a vaccine therefrom
US4328208A (en) Vaccine against chlamydous infections of farm animals
CN110507819B (zh) 青蒿琥酯作为免疫佐剂在制备狂犬病疫苗中的应用
US2915436A (en) Process for the attenuation of infectious canine hepatitis virus and a vaccine prepared therefrom
US3704203A (en) Transmissible gastroenteritis vaccines and methods of producing the same
McLeod Antigenicity in rabbits and relation to immunity
Marsden et al. Behaviour of a Peru strain of Trypanosoma cruzi in Rhesus monkeys
RU2634247C2 (ru) Способ стимуляции иммунного ответа и препарат для его осуществления
SU596241A1 (ru) Адъювант
US3096247A (en) Infectious rhinotracheitis virus attenuated in lamb cell tissue cultures
SU826744A1 (ru) ВАКЦИНА ПРОТИВ ХЛАМИДИОЗА СЕЛЬСКОХОЗЯЙСТВЕННЫХ ЖИВОТНЫХ, содержащая антигенную жидкость из суспензии клеток желточного мешка куриного эмбриона,зараженного хламидиями
GB1058340A (en) Transmissible gastroenteritis vaccines and method of producing the same
RU2056861C1 (ru) Ассоциированная вакцина против сибирской язвы и ящура и способ профилактики сибирской язвы и ящура